AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05896748
Drug: Rilpivirine - Injectable Suspension (RPV LA)
RxNorm normalized name: rilpivirine Injection
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Trial: NCT06414096
Drug: Follicle Stimulating Hormone
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsatile FSH administration via a portable pump.
Trial: NCT05693844
Drug: Albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously at dose of 100-200mg/m2 on day -5
Trial: NCT05693844
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
Trial: NCT00002311
Drug: Wobenzym
RxNorm normalized name: Bromelains/Chymotrypsin/Pancreatin/Papain/Rutosid/Trypsin 45 MG-1 MG-100 MG-60 MG-50 MG-24 MG Oral Tablet, Enteric Coated [WOBENZYM N]
DrugBank: Chymotrypsin (DB09375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05672199
Drug: Efavaleukin alfa
RxNorm normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT06648681
Drug: Lemborexant 5 mg
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention is the oral administration of a study drug containing lemborexant 5 mg daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge or until the first diagnosis of delirium, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, within 1 hour, another insomnia medication may be administered.~IV. The attending physician agrees that the drug can be safely started.~The medication will be held if the patient has been re-intubated, or upon clinical judgement by attending physician.
Trial: NCT00506610
Drug: T-62
RxNorm normalized name: T-62
DrugBank: T-62 (DB12919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04240054
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
Trial: NCT04240054
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
Trial: NCT04240054
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
Trial: NCT05357430
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
Trial: NCT05357430
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
Trial: NCT05357430
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
Trial: NCT04616248
Drug: Poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT04616248
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04616248
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT05448443
Drug: AD981
RxNorm normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration of AD981 in the morning and before sleep for 14 days
Trial: NCT06387160
Drug: as per institutional protocol
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Treatment will be given to the patients as per institutional protocol
Trial: NCT06217302
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral sotagliflozin (200 mg per day)
Trial: NCT05569811
Drug: Patritumab deruxtecan
RxNorm normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
Trial: NCT05569811
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
Trial: NCT05172999
Drug: Polyethylene Glycol Loxenatide
RxNorm normalized name: Polyethylene Glycol Loxenatide
DrugBank: Pegloxenatide (DB19230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
Trial: NCT04805827
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 600 mg Gabapentin
Trial: NCT04805827
Drug: Neurontin
RxNorm normalized name: Neurontin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 capsule contains 2\*300 = 600 mg Gabapentin
Trial: NCT00000671
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000671
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05718544
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
Trial: NCT05718544
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
Trial: NCT04856891
Drug: AK002
RxNorm normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
Trial: NCT05633615
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05633615
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT06164392
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
Trial: NCT06184399
Drug: Ivermectin 1.5 mg ODT
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oro-dispersible tablets of 1.5 mg ivermectin
Trial: NCT06184399
Drug: Ivermectin 3 mg Oral Tablet
RxNorm normalized name: ivermectin 3 MG Oral Tablet
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 3 mg ivermectin
Trial: NCT06184399
Drug: Albendazole 400 mg Oral Tablet
RxNorm normalized name: albendazole 400 MG Oral Tablet
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 400 mg albendazole
Trial: NCT05140941
Drug: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
RxNorm normalized name: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
Trial: NCT05664191
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion at 0.1 µg/kg/min at day 1 and day 8
Trial: NCT06530810
Drug: HS-10382+Flumatinib
RxNorm normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily
Trial: NCT06518902
Drug: mesenchymal stem cells (umbilical cord) injection
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
Trial: NCT06460038
Drug: Tenapanor
RxNorm normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhibitor of NHE3
Trial: NCT05794971
Drug: Regorafenib and DIBIRI
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
Trial: NCT05794971
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
Trial: NCT05356104
Drug: Exenatide extended release
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg once weekly via subcutaneous injection
Trial: NCT06027086
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
Trial: NCT05267054
Drug: Ociperlimab
RxNorm normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT05267054
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT05267054
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered intravenously
Trial: NCT04990336
Drug: Rhubarb single medicine
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb single medicine
Trial: NCT06403670
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
Trial: NCT05048732
Drug: 18F-FluorApoTrace
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -The dose of 18F-FluorApoTrace to be given is 5 mCi
Trial: NCT05399459
Drug: Rimegepant 25 MG
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 25 mg orally disintegrating tablet of rimegepant
Trial: NCT05399459
Drug: Rimegepant 75 MG
RxNorm normalized name: rimegepant 75 MG
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 75 mg orally disintegrating tablet of rimegepant
Trial: NCT04758871
Drug: Dydrogesterone 10 MG Oral Tablet
RxNorm normalized name: dydrogesterone 10 MG Oral Tablet
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg three times daily
Trial: NCT04758871
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2x 200 mg vaginal tablets two times daily
Trial: NCT06255028
Drug: Lymphodepleting Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDC as prespecified in the protocol.
Trial: NCT06377540
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year.
Trial: NCT06377540
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
Trial: NCT06377540
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
Trial: NCT06377540
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
Trial: NCT06377540
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
Trial: NCT06801158
Drug: use of anticancer drugs in monotherapy or in combination therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICSRs involving antineoplastic or immunomodulating agents were included.
Trial: NCT04444349
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
Trial: NCT04832087
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care Teduglutide dosing
Trial: NCT05316688
Drug: Tozuleristide
RxNorm normalized name: Tozuleristide
DrugBank: Tozuleristide (DB15375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05271162
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10 mg q.d; p.o
Trial: NCT05384587
Drug: asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Supplied in 40 mg and 100 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
Trial: NCT05957718
Drug: TKTX cream
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TKTX cream was used in several studies on Tatto and laser
Trial: NCT05617859
Drug: Lenvatinib mesylate capsule
RxNorm normalized name: Lenvatinib Mesylate
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
Trial: NCT04755244
Drug: evorpacept
RxNorm normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusion protein that blocks CD47-SIRPalpha pathway
Trial: NCT04755244
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCL-2 inhibitor
Trial: NCT04755244
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hypomethylating agent (HMA)
Trial: NCT00002189
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04916002
Drug: vidutolimod
RxNorm normalized name: Vidutolimod
DrugBank: Vidutolimod (DB17500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
Trial: NCT04916002
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
Trial: NCT05570825
Drug: CXCR1/2 Inhibitor SX-682
DrugBank: SX-682 (DB19210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05755737
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
Trial: NCT05910177
Drug: Karelizumab combined with etoposide and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
Trial: NCT05841381
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrotinib: 400mg orally daily for 1 year
Trial: NCT05534087
Drug: mFOLFIRINOX-FOLFIRI intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2
Trial: NCT05798845
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toripalimab 240mg ivgtt d4, d24 (2 cycles)
Trial: NCT05798845
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
Trial: NCT05841381
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
Trial: NCT05798845
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toripalimab 240mg ivgtt d1, d22 (2 cycles)
Trial: NCT05841381
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg/m2 per week for a total of 12 weeks
Trial: NCT06637332
Drug: Daptomycin for Injection
RxNorm normalized name: Daptomycin for Injection
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
Trial: NCT06637332
Drug: Vancomycin (IV)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care